Prevalence of hereditary breast and ovarian cancer predisposition gene mutations among 882 HBOC high-risk Chinese individuals.
Identification of deleterious variants in HBOC susceptibility genes allows for increased clinical surveillance and early detection, and could predict the response to PARP inhibitor in patient with advanced ovarian carcinomas. To determine the prevalence and clinical prediction factors for hereditary breast and ovarian carcinoma syndrome, 882 selected individuals underwent multigene panel testing for hereditary breast and ovarian cancer (HBOC) risk assessment at the period from January 2015 to March 2018. Overall, 176 deleterious mutations were observed in 19.50% (n = 172) individuals. 26 of 176 mutations were not previously as well as archived in public database. Among patients with ovarian cancer, 115 deleterious mutations were identified in 429 patients (48.6%) with significant enrichment for a family history of breast or ovarian cancer syndrome (p < 0.05). In breast cancer subgroup, 31 deleterious mutations were identified in 261 patients. Besides BRCA1 (8; 25.8%) and BRCA2 (11; 35.5%), most occurred genes, an additional 12 deleterious mutations (38.7%) were found in 7 other susceptibility genes. Higher mutation incidence (57.9%) was observed in subjects with histories of breast and ovarian cancer. Our results highlighted the genetic heterogeneity of HBOC and the efficiency of multigene panel in performing risk assessment.